Carmo Marta, Gonçalves Francisco Q, Canas Paula M, Oses Jean-Pierre, Fernandes Francisco D, Duarte Filipe V, Palmeira Carlos M, Tomé Angelo R, Agostinho Paula, Andrade Geanne M, Cunha Rodrigo A
CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Br J Pharmacol. 2019 Sep;176(18):3666-3680. doi: 10.1111/bph.14771. Epub 2019 Aug 1.
Parkinson's disease (PD) involves an initial loss of striatal dopamine terminals evolving into degeneration of dopamine neurons in substantia nigra (SN), which can be modelled by 6-hydroxydopamine (6-OHDA) administration. Adenosine A receptor blockade attenuates PD features in animal models, but the source of the adenosine causing A receptor over-activation is unknown. As ATP is a stress signal, we have tested if extracellular catabolism of adenine nucleotides into adenosine (through ecto-5'-nucleotidase or CD73) leads to A receptor over-activation in PD.
Effects of blocking CD73 with α,β-methylene ADP (AOPCP) were assayed in 6-OHDA-treated rats and dopamine-differentiated neuroblastoma SH-SY5Y cells.
6-OHDA increased ATP release and extracellular conversion into adenosine through CD73 up-regulation in SH-SY5Y cells. Removing extracellular adenosine with adenosine deaminase, blocking CD73 with AOPCP, or blocking A receptors with SCH58261 were equi-effective in preventing 6-OHDA-induced damage in SH-SY5Y cells. In vivo striatal exposure to 6-OHDA increased ATP release and extracellular formation of adenosine from adenosine nucleotides and up-regulated CD73 and A receptors in striatal synaptosomes. Intracerebroventricular administration of AOPCP phenocopied effects of SCH58261, attenuating 6-OHDA-induced (a) increase of contralateral rotations after apomorphine, (b) reduction of dopamine content in striatum and SN, (c) loss of TH staining in striatum and SN, (d) motor dysfunction in the cylinder test, and (e) short-term memory impairment in the object recognition test.
Our data indicate that increased ATP-derived adenosine formation is responsible for A receptor over-activation in PD, suggesting CD73 as a new target to manage PD.
帕金森病(PD)最初表现为纹状体多巴胺能终末丧失,进而发展为黑质(SN)多巴胺能神经元变性,这一过程可通过给予6-羟基多巴胺(6-OHDA)来模拟。腺苷A受体阻断可减轻动物模型中的PD特征,但导致A受体过度激活的腺苷来源尚不清楚。由于ATP是一种应激信号,我们测试了腺嘌呤核苷酸通过胞外5'-核苷酸酶或CD73进行胞外分解代谢生成腺苷是否会导致PD中A受体过度激活。
在6-OHDA处理的大鼠和多巴胺分化的神经母细胞瘤SH-SY5Y细胞中检测用α,β-亚甲基ADP(AOPCP)阻断CD73的效果。
6-OHDA通过上调SH-SY5Y细胞中的CD73增加ATP释放并使其胞外转化为腺苷。用腺苷脱氨酶去除胞外腺苷、用AOPCP阻断CD73或用SCH58261阻断A受体在预防6-OHDA诱导的SH-SY5Y细胞损伤方面效果相当。在体内,纹状体暴露于6-OHDA会增加ATP释放以及腺苷从腺苷核苷酸的胞外生成,并上调纹状体突触体中的CD73和A受体。脑室内注射AOPCP可模拟SCH58261的作用,减轻6-OHDA诱导的:(a)阿扑吗啡后对侧旋转增加;(b)纹状体和SN中多巴胺含量降低;(c)纹状体和SN中酪氨酸羟化酶(TH)染色丧失;(d)圆筒试验中的运动功能障碍;(e)物体识别试验中的短期记忆损害。
我们的数据表明,ATP衍生的腺苷生成增加是PD中A受体过度激活的原因,提示CD73作为治疗PD的新靶点。